A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
Latest Information Update: 10 Nov 2023
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Paclitaxel
- Indications Neuropathic pain
- Focus Therapeutic Use
Most Recent Events
- 17 Oct 2023 Results assessing assess whether omega-3 fatty acids could decrease P-APS and thus CIPN published in the Supportive Care in Cancer
- 04 Oct 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2022 Planned End Date changed from 20 Aug 2021 to 31 Jul 2023.